Dilcoran (Pentaerithrityl Tetranitrate) is used to help manage symptomatic patterns associated with chronic stable angina pectoris. The compound is primarily used for the treatment of angina pectoris. Its role is as a foundation for sustained symptomatic management of heart conditions, rather than for the immediate relief of acute episodes.

Therapeutic Role

This medication is part of symptomatic management to reduce the overall symptom burden of chest discomfort linked to stable ischemic heart diseases, which include conditions involving recurrent or episodic manifestations. It assists in addressing the typical symptom clusters that may be triggered by physical exertion, including symptoms related to physical discomfort.

By providing sustained antianginal support, Dilcoran helps to alleviate symptoms that interfere with daily functioning that manifest at lower levels of physical effort. This use supports the patient during episodes of heightened discomfort by assisting with functional stability and contributes to day-to-day comfort. It is used as a foundation of continuous background therapy, applied across domains where additional symptomatic support is needed.

Quick Fact: Support for Exertion-Related Symptoms

Dilcoran is used in clinical scenarios where symptoms create noticeable physiological strain during activity. This profile supports sustained symptomatic management, contributing to easing the overall symptom load during symptomatic periods.

Dilcoran (Pentaerithrityl Tetranitrate) eligibility is strictly defined by regulatory mandates that outline patient populations who must not use the medicine.

Absolute Contraindications

Official labeling strictly contraindicates use in patients with severe anemia or known hypersensitivity to organic nitrates. Use is also absolutely prohibited in individuals who have recently taken a PDE5 inhibitor (such as sildenafil) within the last 24 hours, due to the risk of severe hypotension.

Population and Condition Restrictions

Regulatory warnings define groups for whom use is restricted or requires special caution. These include patients with hypertrophic cardiomyopathy or conditions that increase pressure, such as head trauma or cerebral hemorrhage.

Age and Life Stage Eligibility

The medicine is not established for use in the pediatric population (children) and is not approved by the FDA for this age group. Use during both pregnancy and lactation is classified as conditional, requiring caution as human data are limited or unavailable. Importantly, the FDA has withdrawn approval for all Pentaerithrityl Tetranitrate drug applications in the United States due to lack of substantial evidence of effectiveness.

Interactions with other medicines and products

Official regulatory documentation for Pentaerithrityl Tetranitrate (Dilcoran) strictly defines several interaction patterns based primarily on pharmacodynamic effects.

Formal Contraindications

Co-administration with specific drug classes is formally contraindicated due to the severe risk of systemic hypotension, which is a significant drop in blood pressure. This includes Phosphodiesterase type 5 (PDE5) inhibitors (such as Sildenafil, Tadalafil, and Vardenafil) and Soluble Guanylate Cyclase (sGC) Stimulators (such as Riociguat). These combinations result in a dangerous pharmacodynamic reinforcement of vasodilatory effects, according to official prescribing information.

Documented Pharmacodynamic and Substance Interactions

Interaction Type	Interacting Substance/Class	Official Interaction Outcome
Pharmacodynamic Reinforcement	Other Antihypertensive Agents (e.g., Beta-blockers)	May result in additive hypotensive effects (further lowering of blood pressure).
Substance Interaction	Alcohol (Ethanol)	Restricted use due to intensification of the medicine's vasodilatory activities and increased risk of hypotension.
Drug-Food Interaction	Meals	Administration requires a timing separation from food, typically specified as 1/2 hour before or 1 hour after meals, to manage expected drug levels.

No specific CYP-enzyme-mediated or drug-transporter interaction is listed as a critical, label-mandated restriction in the regulatory documentation for this product.

Dilcoran's mechanism is defined by a precise biochemical cascade that acts on the cardiovascular system's regulatory processes. The drug's action involves two primary, interrelated mechanistic domains that create systemic blood vessel relaxation while preserving the capacity for NO release over time.

---

Molecular Bioactivation and Vascular Signaling Activation

This domain describes the drug's molecular targets and the resulting cellular signal. Dilcoran, which is a prodrug, requires activation by the ALDH-2 enzyme to release Nitric Oxide ( NO), which then activates Soluble Guanylate Cyclase ( sGC). This activation leads to an elevation of the secondary messenger cGMP, which is the direct trigger for smooth muscle relaxation throughout the vascular bed.

---

Hemodynamic Modulation and Cardiovascular Workload Reduction

This domain covers the physiological consequence of the cellular action. The resulting relaxation and dilation of blood vessels, predominantly the veins, facilitates peripheral pooling of blood. This pooling reduces the volume of blood returning to the heart (preload), leading to a reduction in myocardial oxygen requirements.

---

️ ALDH-2 Enzyme Protection Against Tolerance

This unique domain describes how the drug sustains its capacity for NO generation over time. Dilcoran actively promotes the expression of the protective enzyme Heme Oxygenase-1 ( HO-1), which prevents the build-up of oxidative stress that typically deactivates the ALDH-2 enzyme required for bioactivation. This mechanism supports the capacity of the drug's NO releasing capability during continuous administration.

How to Use Dilcoran: Official Administration Guidelines

Dilcoran, a formulation of Pentaerithrityl Tetranitrate (PETN), is administered strictly by the oral route using immediate-release or sustained-action tablets, as defined in prescribing information. The specific administration protocol must adhere to guidelines concerning timing, frequency, and use duration.

Dosing and Frequency

Administration schedules depend on the formulation type:

Formulation	Standard Adult Dosing (Typical Range)	Frequency
Immediate-Release	Initial dose: 10 mg to 20 mg	Four times daily (q.i.d.)
Sustained Action	Standard dose: 80 mg	Twice daily (b.i.d.)

Administration Context and Course

Immediate-release tablets are typically taken in relation to meals, generally administered one-half hour before or one hour after meals and at bedtime, to optimize absorption. Sustained-action forms must be swallowed whole to preserve the timed-release mechanism.

For continuous use, the official administration protocol mandates a daily nitrate-free interval of approximately 10 to 12 hours. This procedural requirement is essential to mitigate the development of pharmacologic tolerance, a recognized principle for long-acting nitrates.

Procedural Rules

• Pediatric Use: The medication is not approved for use in children.
• Discontinuation: If the medication is to be stopped, the dosage must be gradually decreased according to instructions to avoid a potential withdrawal response.

If a dose is missed, it should be taken as soon as possible, unless it is more than 2 hours late; in that case, the missed dose should be skipped.

Research evidence / Overview of studies for Dilcoran

Evidence from Controlled Trials for Chronic Stable Angina Prophylaxis

Research examined Dilcoran's use in conditions characterized by fluctuating or episodic manifestations, specifically chronic stable angina pectoris. The evidence base primarily relies on short-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies monitored adult patients diagnosed with stable coronary artery disease, many of whom were already on other forms of anti-anginal treatment.

The research was conducted during periods of increased symptom activity and focused on outcomes reflecting daily functioning or activity level. The main study outcome measured Total Exercise Duration (TED) during standardized treadmill testing. Other outcomes studied for were the time to the onset of angina symptoms and the time to the point of observable ischemia during exercise.

Findings for the Overall Patient Population

In the largest trial that was evaluated in the general, unselected group of adult patients with stable angina, the measurements of the primary outcome (TED) were reported as not being substantially different from the measurements observed in the placebo group. This finding indicates that the research does not determine whether an individual will respond similarly. An official regulatory assessment of the data cited an overall lack of substantial evidence across the general population of patients.

Research on Highly Symptomatic Subgroups

Although the primary endpoint was not met in the overall group, the research explored patterns in certain pre-specified patient subsets. Studies observed that in a highly symptomatic subgroup—defined as patients who had severely reduced exercise capacity at the start of the trial—the measurements for Total Exercise Duration were described as different when compared to the placebo group. These findings describe patterns observed only in this highly symptomatic population, and the data are still emerging regarding consistency outside of this specific subset.

Long-Term Follow-up and Nitrate Tolerance

Dilcoran was studied for its behavior during continuous long-term use. This research examined whether the drug retained its physiological activity over time, addressing the issue of tolerance that research explored with other organic nitrates. The findings suggest that Dilcoran's active ingredient may elicit minimal or no tolerance, highlighting a specific pattern related to tolerance mechanisms.

Research in Specific Patient Groups

Data for certain patient groups, such as children, pregnant women, or older adults with specific comorbidities, remain insufficient within the context of chronic stable angina prophylaxis. Evidence is limited in these specific populations, meaning the results apply only to the populations studied in the major trials (adults).

Key Studies & References

1. Organic Nitrates

How to Store and Dispose of Dilcoran (Pentaerythritol Tetranitrate)

Official regulatory labeling dictates strict conditions for the storage and disposal of this medicine, focusing on maintaining stability and safety.

Required Storage and Handling

Dilcoran must be stored at room temperature in a cool, dry, and well-ventilated place. Storage rules mandate keeping the medicine away from heat, sparks, open flames, and other ignition sources to maintain stability. The product must be kept out of the sight and reach of children. Tablets should be stored in their tightly closed original containers and protected from light and physical damage like shock or friction.

Official Disposal Instructions

Unused or expired Dilcoran must be disposed of according to local, regional, and national regulations. Due to its chemical properties, the product should not be flushed down the toilet or poured into a drain (sewer system). Disposal must be handled as pharmaceutical waste, often requiring the supervision of a specialist.